Shipping: Available products typically ship within 24/48h, via priority shipping.
Do you need support? Contact Customer Service or Technical Support.
Online Account
Access or Create Your Account
Product Details
Alternative Name |
Apo-2L, TNFSF 10, CD253 |
---|---|
Application |
FUNC |
Application Notes |
Induces apoptosis in a concentration range of 1-100ng/ml if applied with the cross-linking enhancer. |
Concentration |
TRAIL: 0.1mg/ml after reconstitutionEnhancer: 1mg/ml after reconstitution |
Contents |
10µg of TRAIL, Soluble (human) (recombinant) (Prod. No. ALX-522-003) and 2×50µg of Enhancer for Ligands (Prod. No. ALX-804-034). |
Formulation |
Lyophilized. Contains PBS. |
Purity |
≥95% (SDS-PAGE) |
Reconstitution |
Reconstitute TRAIL with 100µl and each vial of enhancer with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum. |
Source |
Produced in E. coli. The extracellular domain of human TRAIL (Apo-2L) (aa 95-281) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag. |
Specific Activity |
ED50: 10ng/ml (Jurkat cells) |
Specificity |
TRAIL binds to human and mouse TRAIL receptors and human osteoprotegerin (OPG). |
Technical Info / Product Notes |
FLAG is a registered trademark of Sigma-Aldrich Co. |
UniProt ID |
P50591 |
Handling & Storage
Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. |
---|---|
Handling |
Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
Long Term Storage |
-20°C |
Shipping |
Blue Ice |
Regulatory Status |
RUO – Research Use Only |
---|
- Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells: Rizzo, A., Satta, A., et al.; J. Exp. Clin. Cancer Res. 40, 5 (2021), Abstract
- Synergistic anticancer effect of plasma-activated infusion and salinomycin by targeting autophagy and mitochondrial morphology: Ando, T., Suzuki-Karasaki, M., et al.; bioRxiv , (2020)
- Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization: M. Li, et al.; Biochem. Biophys. Res. Commun. 495, 1376 (2018), Abstract
- MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis: Patron, J. P., Fendler, A., et al.; PLoS One 7, e35345 (2012), Abstract
- Human mast cells undergo TRAIL-induced apoptosis: B. Berent-Maoz, et al.; J. Immunol. 176, 2272 (2006), Abstract
- Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells: S. Lacour, et al.; Oncogene 22, 1807 (2003), Abstract
- Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils: I. Daigle, et al.; Nat. Med. 8, 61 (2002), Abstract
- Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L): R. Ravi & A. Bedi; Cancer Res. 62, 1583 (2002), Abstract
- Induction of TRAIL-mediated glioma cell death by human T cells: J. Dörr, et al.; J. Neuroimmunol. 122, 117 (2002), Abstract
- Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells: C. Xiao, et al.; J. Biol. Chem. 277, 25020 (2002), Abstract — Full Text
- TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections: J. Strater, et al.; Gastroenterology 122, 659 (2002), Abstract
- Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-Induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8: T.S. Soderstrom, et al.; J. Immunol. 169, 2851 (2002), Abstract
- TRAIL/Apo-2 ligand induces primary plasma cell apoptosis: J. Ursini-Siegel, et al.; J. Immunol. 169, 5505 (2002), Abstract — Full Text
- Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells: J.D. Lunemann, et al.; J. Immunol. 168, 4881 (2002), Abstract
- Caspase-10 is an initiator caspase in death receptor signaling: J. Wang, et al.; PNAS 98, 13884 (2001), Abstract — Full Text
- The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines: Q. Liao, et al.; FEBS Lett. 503, 151 (2001), Abstract
- Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2: C.A. Benedict et al.; J. Biol. Chem. 276, 3270 (2001), Abstract — Full Text
- A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells: V. Screpanti, et al.; J. Immunol. 167, 2068 (2001), Abstract — Full Text
- NF-κB signals induce the expression of c-FLIP: O. Micheau, et al.; Mol. Cell. Biol. 21, 5299 (2001), Abstract — Full Text
- Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan: M. Dejosez, et al.; Cell Death Differ. 7, 1127 (2000), Abstract — Full Text
Related Products

Alternative Name | Apo-2L, TNFSF 10, CD253 |
---|---|
Purity | ≥90% (SDS-PAGE) |
Source | Produced in E. coli. The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag. |
Enhancer for Ligands
ALX-804-034
Enhances biological activity of TRAIL, soluble (human) (recombinant) and FasL, soluble (human) (recombinant).

Datasheet, Manuals, SDS & CofA
Manuals And Inserts
Certificate of Analysis
Please enter the lot number as featured on the product label
SDS
Enzo Life Science provides GHS Compliant SDS
If your language is not available please fill out the SDS request form